يعرض 1 - 20 نتائج من 31 نتيجة بحث عن '"vasculotropin A/ec [Endogenous Compound]"', وقت الاستعلام: 0.63s تنقيح النتائج
  1. 1
  2. 2
  3. 3
    Electronic Resource

    مصطلحات الفهرس: meta analysis, multiple myeloma/dt [Drug Therapy], observational study, oncology, ovary cancer/dt [Drug Therapy], peer review, phase 2 clinical trial (topic), phase 3 clinical trial (topic), priority journal, prostate cancer/dt [Drug Therapy], QT prolongation/si [Side Effect], randomized controlled trial (topic), review, systematic review, venous thromboembolism/si [Side Effect], abiraterone/ae [Adverse Drug Reaction], abiraterone/ct [Clinical Trial], abiraterone/dt [Drug Therapy], aflibercept/ae [Adverse Drug Reaction], aflibercept/ct [Clinical Trial], androgen receptor/ec [Endogenous Compound], axitinib/ae [Adverse Drug Reaction], axitinib/ct [Clinical Trial], bevacizumab/ae [Adverse Drug Reaction], bevacizumab/ct [Clinical Trial], bevacizumab/dt [Drug Therapy], cediranib/ae [Adverse Drug Reaction], cediranib/ct [Clinical Trial], cetuximab/ae [Adverse Drug Reaction], cetuximab/ct [Clinical Trial], cytochrome P450 family 17/ec [Endogenous Compound], enzalutamide/ae [Adverse Drug Reaction], enzalutamide/ct [Clinical Trial], enzalutamide/dt [Drug Therapy], epidermal growth factor receptor 2/ec [Endogenous Compound], estrogen receptor alpha/ec [Endogenous Compound], estrogen receptor beta/ec [Endogenous Compound], Flt3 ligand/ec [Endogenous Compound], lenalidomide/ae [Adverse Drug Reaction], lenalidomide/ct [Clinical Trial], lenalidomide/dt [Drug Therapy], nintedanib/ae [Adverse Drug Reaction], nintedanib/ct [Clinical Trial], panitumumab/ae [Adverse Drug Reaction], panitumumab/ct [Clinical Trial], pazopanib/ae [Adverse Drug Reaction], pazopanib/ct [Clinical Trial], platelet derived growth factor alpha receptor/ec [Endogenous Compound], platelet derived growth factor beta receptor/ec [Endogenous Compound], protein Ret/ec [Endogenous Compound], Raf protein/ec [Endogenous Compound], ramucirumab/ae [Adverse Drug Reaction], ramucirumab/ct [Clinical Trial], sorafenib/ae [Adverse Drug Reaction], sorafenib/ct [Clinical Trial], sorafenib/dt [Drug Therapy], sunitinib/ae [Adverse Drug Reaction], sunitinib/ct [Clinical Trial], tamoxifen/ae [Adverse Drug Reaction], tamoxifen/ct [Clinical Trial], tamoxifen/dt [Drug Therapy], thalidomide/ae [Adverse Drug Reaction], thalidomide/ct [Clinical Trial], thalidomide/dt [Drug Therapy], transcription factor/ec [Endogenous Compound], trastuzumab/ae [Adverse Drug Reaction], trastuzumab/ct [Clinical Trial], trastuzumab/dt [Drug Therapy], unclassified drug, vandetanib/ae [Adverse Drug Reaction], vandetanib/ct [Clinical Trial], vandetanib/dt [Drug Therapy], vasculotropin A/ec [Endogenous Compound], vasculotropin receptor 1/ec [Endogenous Compound], vasculotropin receptor 3/ec [Endogenous Compound], cytochrome P450 family 17a1/ec [Endogenous Compound], lymphoid transcription factor ikzf1/ec [Endogenous Compound], lymphoid transcription factor ikzf3/ec [Endogenous Compound], molecularly targeted therapy, arterial thromboembolism/si [Side Effect], breast cancer/dt [Drug Therapy], cardiology, cardiotoxicity/si [Side Effect], castration resistant prostate cancer/dt [Drug Therapy], clinician, Cochrane Library, cohort analysis, congestive heart failure/si [Side Effect], controlled study, drug megadose, Embase, female, general practice, heart left ventricle ejection fraction, human, hypertension/si [Side Effect], low drug dose, lung cancer/dt [Drug Therapy], male, Medline, Review

  4. 4
    Electronic Resource
  5. 5
    Electronic Resource
  6. 6
    Electronic Resource

    مصطلحات الفهرس: mouse, mRNA expression level, newborn, nonhuman, phase contrast microscopy, protein analysis, pulmonary hypertension/dt [Drug Therapy], real time polymerase chain reaction, reverse transcription polymerase chain reaction, spectrophotometry, synchrotron radiation, X ray analysis, 15 hydroxy 11alpha,9alpha epoxymethanoprosta 5,13 dienoic acid, alpha smooth muscle actin/ec [Endogenous Compound], endothelin 1/ec [Endogenous Compound], endothelin receptor/ec [Endogenous Compound], galectin 3/ec [Endogenous Compound], interleukin 1/ec [Endogenous Compound], interleukin 1 receptor blocking agent/dt [Drug Therapy], interleukin 1 receptor blocking agent/sc [Subcutaneous Drug Administration], lipopolysaccharide, monocyte chemotactic protein 1/ec [Endogenous Compound], thromboxane, vasculotropin/ec [Endogenous Compound], vasculotropin A/ec [Endogenous Compound], intravascular ultrasound system, phase contrast microscope, spectrophotometer, time to peak velocity, Eclipse Ti U, NanoDrop 100, ViVid 7, micro-computed tomography, heart left ventricle function, heart muscle fibrosis, heart rate, heart right ventricle function, heart ventricle ejection time, heart ventricle enddiastolic pressure, heart ventricle remodeling, hyperoxia, image analysis, immunohistochemistry, lung artery pressure, lung dysplasia/dt [Drug Therapy], algorithm, angiogenesis, animal experiment, animal model, animal tissue, arterial pressure, article, blood vessel diameter, cardiovascular parameters, carditis, chorioamnionitis, cineangiocardiography, echocardiography, enzyme linked immunosorbent assay, gene expression, gestational age, lung vascular resistance, mean arterial pressure, Article

    URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/36042
    Frontiers in Immunology
    Click here for full text options
    LibKey Link

  7. 7
    Electronic Resource

    مصطلحات الفهرس: mouse, mRNA expression level, newborn, nonhuman, phase contrast microscopy, protein analysis, pulmonary hypertension/dt [Drug Therapy], real time polymerase chain reaction, reverse transcription polymerase chain reaction, spectrophotometry, synchrotron radiation, X ray analysis, 15 hydroxy 11alpha,9alpha epoxymethanoprosta 5,13 dienoic acid, alpha smooth muscle actin/ec [Endogenous Compound], endothelin 1/ec [Endogenous Compound], endothelin receptor/ec [Endogenous Compound], galectin 3/ec [Endogenous Compound], interleukin 1/ec [Endogenous Compound], interleukin 1 receptor blocking agent/dt [Drug Therapy], interleukin 1 receptor blocking agent/sc [Subcutaneous Drug Administration], lipopolysaccharide, monocyte chemotactic protein 1/ec [Endogenous Compound], thromboxane, vasculotropin/ec [Endogenous Compound], vasculotropin A/ec [Endogenous Compound], intravascular ultrasound system, phase contrast microscope, spectrophotometer, time to peak velocity, Eclipse Ti U, NanoDrop 100, ViVid 7, micro-computed tomography, heart left ventricle function, heart muscle fibrosis, heart rate, heart right ventricle function, heart ventricle ejection time, heart ventricle enddiastolic pressure, heart ventricle remodeling, hyperoxia, image analysis, immunohistochemistry, lung artery pressure, lung dysplasia/dt [Drug Therapy], algorithm, angiogenesis, animal experiment, animal model, animal tissue, arterial pressure, article, blood vessel diameter, cardiovascular parameters, carditis, chorioamnionitis, cineangiocardiography, echocardiography, enzyme linked immunosorbent assay, gene expression, gestational age, lung vascular resistance, mean arterial pressure, Article

  8. 8
    Electronic Resource

    URL: Clinical and Experimental Pharmacology and Physiology
    Click here for full text options
    LibKey Link

  9. 9
    Electronic Resource

    URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/37125
    Clinical and Experimental Pharmacology and Physiology
    Click here for full text options
    LibKey Link

  10. 10
    Electronic Resource
  11. 11
    Electronic Resource
  12. 12
    Electronic Resource
  13. 13
    Electronic Resource

    URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/39765
    Pediatric Research
    Click here for full text options
    LibKey Link

  14. 14
    Electronic Resource

    مصطلحات الفهرس: priority journal, progression free survival, randomized controlled trial, side effect/si [Side Effect], skin disease/si [Side Effect], soft tissue disease/si [Side Effect], South Korea, stomach adenocarcinoma/dt [Drug Therapy], subcutaneous tissue disorder/si [Side Effect], alanine aminotransferase/ec [Endogenous Compound], aspartate aminotransferase/ec [Endogenous Compound], epidermal growth factor receptor 2/ec [Endogenous Compound], gamma glutamyltransferase/ec [Endogenous Compound], placebo, regorafenib/ae [Adverse Drug Reaction], regorafenib/ct [Clinical Trial], regorafenib/cm [Drug Comparison], regorafenib/dt [Drug Therapy], regorafenib/po [Oral Drug Administration], trastuzumab/dt [Drug Therapy], vasculotropin A/ec [Endogenous Compound], liver failure/si [Side Effect], abdominal pain/si [Side Effect], adult, advanced cancer/dt [Drug Therapy], aged, alanine aminotransferase blood level, anorexia/si [Side Effect], article, aspartate aminotransferase blood level, Australia, Canada, cancer chemotherapy, cancer survival, controlled study, disease course, double blind procedure, female, follow up, gamma glutamyl transferase blood level, gastrointestinal disease/si [Side Effect], human, hypertension/si [Side Effect], hypophosphatemia/si [Side Effect], infection/si [Side Effect], major clinical study, male, metabolic disorder/si [Side Effect], multicenter study, neutrophil lymphocyte ratio, New Zealand, nutritional disorder/si [Side Effect], pain/si [Side Effect], phase 2 clinical trial, Article

    URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/39709
    Journal of Clinical Oncology
    Click here for full text options
    LibKey Link

  15. 15
    Electronic Resource
  16. 16
    Electronic Resource
  17. 17
    Electronic Resource

    مصطلحات الفهرس: priority journal, progression free survival, randomized controlled trial, side effect/si [Side Effect], skin disease/si [Side Effect], soft tissue disease/si [Side Effect], South Korea, stomach adenocarcinoma/dt [Drug Therapy], subcutaneous tissue disorder/si [Side Effect], alanine aminotransferase/ec [Endogenous Compound], aspartate aminotransferase/ec [Endogenous Compound], epidermal growth factor receptor 2/ec [Endogenous Compound], gamma glutamyltransferase/ec [Endogenous Compound], placebo, regorafenib/ae [Adverse Drug Reaction], regorafenib/ct [Clinical Trial], regorafenib/cm [Drug Comparison], regorafenib/dt [Drug Therapy], regorafenib/po [Oral Drug Administration], trastuzumab/dt [Drug Therapy], vasculotropin A/ec [Endogenous Compound], liver failure/si [Side Effect], abdominal pain/si [Side Effect], adult, advanced cancer/dt [Drug Therapy], aged, alanine aminotransferase blood level, anorexia/si [Side Effect], article, aspartate aminotransferase blood level, Australia, Canada, cancer chemotherapy, cancer survival, controlled study, disease course, double blind procedure, female, follow up, gamma glutamyl transferase blood level, gastrointestinal disease/si [Side Effect], human, hypertension/si [Side Effect], hypophosphatemia/si [Side Effect], infection/si [Side Effect], major clinical study, male, metabolic disorder/si [Side Effect], multicenter study, neutrophil lymphocyte ratio, New Zealand, nutritional disorder/si [Side Effect], pain/si [Side Effect], phase 2 clinical trial, Article

    URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/39709
    Journal of Clinical Oncology
    LibKey Link

  18. 18
  19. 19
  20. 20
    Electronic Resource

    URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/27514
    Click here for full text options
    LibKey Link